The Biosimilar Clinical Development Process
An introduction to the key steps in the biosimilar development process.
Biologics: Reference Medicines and Biosimilars
An introduction to biologics and biosimilars, their similarities and respective roles in the treatment pathway.
Biologics are complex successor medicines to existing biologics.1 Both are produced by living cells under tightly controlled and sterile conditions. Existing biologics and their biosimilars have an indistinguishable structure and offer the same outcomes.2
References:
1. Skingle D. RMD Open 2015;1(1):e000141.
2. EMA. Biosimilars in the EU. Available at: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. [Last accessed April 2022].
These materials are intended for healthcare professionals only. This page is sponsored by Sandoz.
Was this content helpful?
You Might Also Be Interested In:
